Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Staff photo / Brian Yauger South Range’s Ayden Leon brings down a pass against Cardinal Mooney’s Ty Reali Friday night at Girard’s Arrowhead Stadium. GIRARD — Both South Range and Cardinal ...

Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, touching an all-time high of $126.3. According to InvestingPro analysis, the stock remains undervalued despite this milestone ...

Jan 14 (Reuters) - Cardinal Health (CAH.N), opens new tab said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for ...

Wells Fargo raised the firm’s price target on Cardinal Health (CAH) to $135 from $127 and keeps an Equal Weight rating on the shares following ...

Leerink Partners analyst Michael Cherny has maintained their bullish stance on CAH stock, giving a Buy rating on January 15.Stay Ahead of the ...

Clemson was very efficient against the Cardinal, shooting over 40 percent from the field and 3-point range. Winning the 3-point line has been key for the Tigers all season, and it was a massive ...